目的 探討金烏骨通膠囊聯(lián)合骨肽片治療頸椎骨質(zhì)增生的臨床療效。方法 選取2019年5月-2020年5月在中國(guó)平煤神馬醫(yī)療集團(tuán)總醫(yī)院進(jìn)行治療的226例頸椎骨質(zhì)增生患者為研究對(duì)象，根據(jù)就診順序分為對(duì)照組（113例）和治療組（113例）。對(duì)照組口服骨肽片，0.6 g/次，3次/d；治療組在對(duì)照組基礎(chǔ)上口服金烏骨通膠囊，1.5 g/次，3次/d。兩組均經(jīng)15 d治療。比較兩組的臨床療效，觀察兩組治療前后中醫(yī)癥候積分、相關(guān)評(píng)分和椎動(dòng)脈血流速度參數(shù)的變化情況。結(jié)果 治療后，治療組總有效率是97.35%顯著高于對(duì)照組的82.30%（P<0.05）。治療后，兩組頸項(xiàng)酸痛積分、肩背酸痛積分、活動(dòng)受限積分、肢體麻木積分、頭暈?zāi)垦７e分等中醫(yī)癥候積分均較治療前顯著降低（P<0.05）；治療后，治療組這些中醫(yī)癥候積分顯著低于對(duì)照組（P<0.05）。治療后，兩組CASCS評(píng)分、ESCV評(píng)分、QLQC30評(píng)分均顯著升高，但NDI評(píng)分顯著降低（P<0.05）；治療后，治療組CASCS評(píng)分、ESCV評(píng)分、QLQC30評(píng)分顯著高于對(duì)照組，而NDI評(píng)分顯著低于對(duì)照組（P<0.05）。經(jīng)治療，兩組平均血流速度（V_M）、舒張末期血流速度（V_D）、收縮期血流速度（V_P）均較治療前顯著升高（P<0.05）；治療后治療組這些椎動(dòng)脈血流速度參數(shù)顯著高于對(duì)照組（P<0.05）。結(jié)論 金烏骨通膠囊聯(lián)合骨肽片治療頸椎骨質(zhì)具有較好的臨床療效，可有效改善患者臨床癥狀，提高頸部活動(dòng)能力，改善眩暈程度及椎動(dòng)脈血流速度，有利于提高患者生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Jinwu Gutong Capsules mbined with Ossotide Tablets in treatment of cervical hyperosteogeny. Methods 226 Patients with cervical hyperosteogeny admitted to China Pingmei Shenma Medical Group General Hospital from May 2019 to May 2020 were divided into control group (113 cases) and treatment group (113 cases) according to the order of treatment. The control group was po administered with Ossotide Tablets, 0.6 g/time, three times dialy. The treatment group was po administered with Jinwu Gutong Capsules on the basis of the control group, 1.5 g/time, three times dialy. All patients were treated for 15 days. The clinical efficacy of the two groups was compared, and the changes of TCM syndrome scores, correlation scores and vertebral artery blood flow velocity parameters in two groups before and after treatment were observed. Results After treatment, the total effective rate in the treatment group was 97.35%, significantly higher than that in the control group (82.30%, P < 0.05). After treatment, the scores of traditional Chinese medicine symptoms such as neck pain, shoulder and back pain, limited activity, numbness and dizziness in both groups were significantly lower than before treatment (P < 0.05). After treatment, the scores of TCM syndromes in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, CASCS score, ESCV score and QLQC30 score in both groups were significantly increased, but NDI score was significantly decreased (P < 0.05). After treatment, CASCS score, ESCV score and QLQC30 score in the treatment group were significantly higher than those in the control group, while NDI score was significantly lower than that in the control group (P < 0.05). After treatment, average blood flow velocity (V_M), end-diastolic blood flow velocity (V_D) and systolic blood flow velocity (V_P) in both groups were significantly increased compared with that before treatment (P < 0.05). After treatment, the flow velocity parameters of these vertebral arteries in the treatment group were significantly higher than those in the control group (P < 0.05). Conclusion Jinwu Gutong Capsules combined with Ossotide Tablets has good clinical efficacy in treatment of cervical hyperosteogeny, and can effectively improve the clinical symptoms of patients, and can improve the ability to move the neck, improve the degree of vertigo and vertebral artery blood flow speed, and also can conducive to improving the life quality of patients, which has a certain clinical application value.

R977

開封市科技發(fā)展計(jì)劃項(xiàng)目（1903069）